Hemospan: Design principles for a new class of oxygen therapeutic

Artificial Organs

Volumn 33, Issue 2, 2009, Pages 133-138

  Vandegriff, Kim D ^a,b   Winslow, Robert M ^a  

^a SANGART INC   (United States)

^b NONE   (United States)

Author keywords

Clinical trials; Hemospan; Maleimide poly(ethylene) glycol; MalPEG Hb; MP4

Indexed keywords

CROSSLINKING; ETHYLENE; HEMOGLOBIN; POLYOLS;

CLINICAL TRIAL; DESIGN PRINCIPLES; HEMOGLOBIN-BASED OXYGEN CARRIERS; HEMOSPAN; MALEIMIDE POLY(ETHYLENE) GLYCOL; MALEIMIDES; MALPEG-HB; MP4; OXYGEN AFFINITY; SAFETY CONCERNS;

MOLECULAR OXYGEN;

ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOSPAN; MACROGOL; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTENSION; NONHUMAN; OXYGEN AFFINITY; OXYGEN TRANSPORT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; VASOCONSTRICTION;

EID: 57749207472     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2008.00697.x     Document Type: Review

References (39)

1. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 1978 23 : 73 80.
2. Gould SA, Sehgal LR, Rosen AL, et al. Hemoglobin solution: is normal [Hb] or P50 more important? J Surg Res 1982 33 : 189 93.
3. Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MNRG. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. JAMA 1999 282 : 1857 64.
4. Saxena R, Wijnhoud AD, Carton H, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999 30 : 993 6.
5. Winslow R. αα - Crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang 2000 79 : 1 20.
6. Raat NJ. Effects of recombinant hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med 2005 146 : 304 5.
7. Kreiter H, Hagen G, Waschke KF, Wenneis B, Bruckner UB, van Ackern K. Isovolemic hemodilution with a bovine hemoglobin-based oxygen carrier: effects on hemodynamics and oxygen transport in comparison with a nonoxygen-carrying volume substitute. J Cardiothorac Vasc Anesth 1997 11 : 3 9.
8. Torres Filho IP, Spiess BD, Barbee RW, Ward KR, Oldenhof J, Pittman RN. Systemic responses to hemodilution after transfusion with stored blood and with a hemoglobin-based oxygen carrier. Anesth Analg 2005 100 : 912 20.
9. Loscalzo J. Nitric oxide binding and the adverse effects of cell-free hemoglobins: what makes us different from earthworms? J Lab Clin Med 1997 129 : 580 3.
10. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998 16 : 672 6.
11. 2 binding to a maleimide poly(ethylene glycol)-conjugated human haemoglobin. Biochem J 2004 382 : 183 9.
12. Young MA, Riddez L, Kjellström BT, et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med 2005 33 : 1794 804.
13. Rohlfs RJ, Bruner E, Chiu A, et al. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem 1998 273 : 12128 34.
14. Fitzpatrick CM, Savage SA, Kerby JD, Clouse W, Kashyap VS. Resuscitation with a blood substitute causes vasoconstriction without nitric oxide scavenging in a model of arterial hemorrhage. J Am Coll Surg 2004 199 : 693 701.
15. Tsai A, Cabrales P, Manjula B, Acharya S, Winslow R, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 2006 108 : 3603 10.
16. Vandegriff KD, Olson JS. Morphological and physiological factors affecting oxygen uptake and release by red blood cells. J Biol Chem 1984 259 : 12619 27.
17. Lemon DD, Nair PK, Boland EJ, Olson JS, Hellums JD. Physiological factors affecting oxygen transport by hemoglobin in an in vitro capillary system. J Appl Physiol 1987 62 : 798 806.
18. 2 affinity. Am J Physiol 1999 276 : H553 62.
19. Kreuzer F. Facilitated diffusion of oxygen and its possible significance: a review. Respir Physiol 1970 9 : 1 30.
20. Page TC, Light WR, McKay CB, Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res 1998 55 : 54 64.
21. McCarthy M, Vandegriff K, Winslow R. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem 2001 92 : 103 17.
22. 2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Microvasc Res 1996 52 : 58 68.
23. Intaglietta M, Johnson PC, Winslow RM. Microvascular and tissue oxygen distribution. Cardiovasc Res 1996 32 : 632 43.
24. 2 therapeutics. Am J Physiol 2003 285 : H1411 H1419.
25. Budhiraja V, Hellums J. Effect of hemoglobin polymerization on oxygen transport in hemoglobin solutions. Microvasc Res 2002 64 : 220 33.
26. Cole RH, Vandegriff KD, Szeri AJ, Savas O, Baker DA, Winslow RM. A quantitative framework for the design of acellular hemoglobins as blood substitutes: implications of dynamic flow conditions. Biophys Chem 2007 128 : 63 74.
27. Vandegriff KD, Malavalli A, Mkrtchyan GM, Spann SN, Baker DA, Winslow RM. Sites of modification of Hemospan, a poly(ethylene) glycol-modified human hemoglobin for use as an oxygen therapeutic. Bioconjug Chem 2008 Oct 7 [Epub ahead of print KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 2003 43 : 509 16.
28. Manjula BN, Tsai A, Upadhya R, et al. Site-specific PEGylation of hemoglobin at Cys-93(ß): correlation between the colligative properties of the PEGylated protein and the length of the conjugated chain. Bioconjug Chem 2003 14 : 464 72.
29. Vandegriff KD, Malavalli A, Minn C, et al. Oxidation and haeme loss kinetics of poly(ethylene glycol)-conjugated hemoglobin (MP4): dissociation between in vitro and in vivo oxidation rates. Biochem J 2006 399 : 463 71.
30. Svergun DI, Ekström F, Vandegriff KD, et al. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic. Biophys J 2008 94 : 173 81.
31. Winslow RM, Lohman J, Malavalli A, Vandegriff KD. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol 2004 97 : 1527 34.
32. Drobin D, Kjellström BT, Malm E, et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol 2004 96 : 1843 53.
33. Young MA, Lohman J, Malavalli A, Vandegriff KD. Hemospan improves outcome in a model of peri-operative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch. J Cardiothorac Vasc Anesth 2008 Oct 21 [Epub ahead of print C, Ahl T, Johansson T, et al. A multi-center clinical study of the safety and activity of maleimide-polyethylene glycol hemoglobin (Hemospan®) in patients undergoing major orthopedic surgery. Anesthesiology 2006 105 : 1153 63.
34. Vandegriff KD, Young MA, Lohman J, et al. CO-MP4, a poly(ethylene) glycol-conjugated hemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. Br J Pharmacol 2008 154 : 1649 61.
35. Young MA, Riddez L, Kjellström BT, Winslow RM. Effect of MalPEG-hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: comparison with crystalloid and blood. J Trauma 2007 63 : 1234 44.
36. 2 delivery by blood substitutes: in vitro arteriolar simulations of first- and second-generation products. Microvasc Res 2008 76 : 169 79.
37. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008 299 : 2304 12.
38. Keipert P, Olofsson C, Winslow R. Letter to the editor. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 300 : 1295 6.
39. Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica 2005 90 : 505 15.